Prestige Biologics Co., Ltd. (KOSDAQ:334970)
South Korea
· Delayed Price · Currency is KRW 2,390.00
-40.00 (-1.65%)
At close: Apr 28, 2026
Prestige Biologics Revenue
Prestige Biologics had revenue of 8.90B KRW in the quarter ending December 31, 2025, with 194.53% growth. This brings the company's revenue in the last twelve months to 19.24B, up 397.28% year-over-year. In the fiscal year ending June 30, 2025, Prestige Biologics had annual revenue of 12.53B with 477.83% growth.
Revenue (ttm)
19.24B
Revenue Growth
+397.28%
P/S Ratio
9.66
Revenue / Employee
n/a
Employees
n/a
Market Cap
185.83B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 12.53B | 10.36B | 477.83% |
| Jun 30, 2024 | 2.17B | 423.21M | 24.24% |
| Jun 30, 2023 | 1.75B | 1.73B | 11,115.88% |
| Dec 31, 2022 | 15.57M | -3.21B | -99.52% |
| Dec 31, 2021 | 3.23B | - | - |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ensol Biosciences | 537.46M |
| ISU Abxis | 56.67B |
| Genome & Company | 24.59B |
| ABION | 880.14M |
| ViGenCell | 278.95M |
| QuadMedicine | 10.70B |
| CORESTEMCHEMON | 20.16B |
| Bio Solution | 15.20B |